Multiple myeloma (MM) is a plasma cell malignancy characterized by the overproduction of monoclonal immunoglobulins and the presence of hypercalcemia, renal injury, anemia, osteolytic lesions, and frequent infections.
therapies becomes progressively shorter with successive regimens. 7 The current goals of treatment in relapsed MM are focused on identifying optimal drug combinations and the optimal sequence of their use, and determining the place of new agents in the evolving treatment paradigm. Carfilzomib, a next-generation proteasome inhibitor (PI), has recently received approval by the US Food and Drug Administration for the treatment of relapsed and/or refractory MM in patients who have received at least two prior therapies including bortezomib and an immunomodulator (thalidomide or lenalidomide). Herein we provide a summary of the key data for single-agent carfilzomib in the relapsed and/or refractory disease setting.
Carfilzomib-Pharmacology and Preclinical Activity
Carfilzomib is an analog of epoxomicin and eponemycin, a pair of related natural products that were initially shown to inhibit tumors in animals and were later shown to inhibit the chymotrypsin-like (CT-L) activity of the proteasome. [10] [11] [12] [13] [14] At therapeutic concentrations, carfilzomib shows primary selectivity for CT-L activity of the proteasome and displays little activity against the trypsin-like or caspase-like activities. 15 In contrast to the approved boronic acid PI bortezomib, which is a reversible PI, the epoxyketone pharmacophore of carfilzomib forms an irreversible bond with the catalytic β5 subunit of the proteasome and with the analogous subunit β5i (LMP7) of the immunoproteasome (see Figure 1 ).
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In preclinical models of MM, carfilzomib specifically inhibited the activities of both the proteasome and the immunoproteasome by 70-80 % in MM cell lines and primary MM cells, resulting in dose-and time-dependent inhibition of proliferation, leading to apoptosis. 17 Carfilzomib also overcame resistance to other agents including bortezomib and acted synergistically with dexamethasone to enhance apoptosis. 17 In vivo, carfilzomib demonstrated greater antitumor activity than bortezomib. 15, 17 In these same models, carfilzomib showed substantially less off-target activity against non-proteasomal proteases than bortezomib, correlating with significantly less neurotoxicity and neurodegeneration, 15, 17, 18 which may be relevant to the different rates of peripheral neuropathy observed with both agents in the clinical setting.
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Clinical Studies
Phase I Studies
The open-label Phase I studies PX-171-001 (NCT trial number no longer Table 1 ). The best overall response was 16.7 % with a median DOR of 7.2 months (see Table 2 ). 21 The most common treatment-emergent AEs of any grade were anemia (73.9 %), fatigue (69.6 %), and thrombocytopenia (50.0 %). 21 Common grade 3/4 AEs were primarily hematologic and included anemia (37.0 %), lymphopenia (28.3 %), and thrombocytopenia (26.1 %) (see Table 3 ). Peripheral neuropathy and neuropathy-related AEs were generally mild and infrequent during the study. The encouraging efficacy and favorable safety profile observed in this pilot study provided the rationale to expand the protocol under an amendment to enroll approximately 250 additional patients and explore the feasibility of intrapatient dose escalation of carfilzomib from 20 to 27 mg/m 2 .
PX-171-003-A1
The Table 1 ). The primary endpoint was overall response rate (ORR; ≥partial response).
Secondary endpoints included clinical benefit response (≥minimal response), duration of response (DOR), time to progression (TTP), progression-free survival (PFS), OS, and safety. The best ORR was 23.7 % with a median DOR of 7.8 months and median OS of 15.6 months (see Table 2 ). 22 The most common AEs were fatigue (48.9 %), anemia (45.9 %), nausea (44.7 %), and thrombocytopenia (38.7 %) (see Table 3 ), and there was no evidence of cumulative toxicity based on an analysis of the time Table 1 ). These patients achieved a best ORR of 17.1 % (see Table 2 ), with a median DOR >10.6 months and a median TTP of 4.6 months. 25 The most common AEs were fatigue (62.9 %), nausea (60.0 %) (see Table 3 for Cycle 1 and then 27 mg/m 2 for all subsequent cycles) (see Table 1 ).
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The primary endpoint was best overall response. ORRs were 42.4 % in Cohort 1 and 52.2 % in Cohort 2 (see Table 2 ), with median DORs of 13.1 months for patients in Cohort 1 and not reached for patients in Cohort 2. 23 Median TTP was 8.3 months and not reached for Cohorts 1 and 2, respectively. The most common treatment-emergent AEs were fatigue (62.0 %) and nausea (48.8 %) (see Table 3 ). Single-agent 
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PX-171-005
In the PX-171-005 (ClinicalTrial.gov identifier NCT00721734) study, carfilzomib monotherapy was evaluated in 50 patients with varying degrees of renal dysfunction, including some on chronic dialysis, with patients grouped into cohorts according to creatinine clearance (CrCl). 24 In this study, patients received single-agent carfilzomib intravenously twice weekly for three of four weeks for up to 12 cycles.
The dose given during Cycle 1 was 15 mg/m 2 , increased to 20 mg/m 2 in Cycle 2, and to 27 mg/m 2 in Cycle 3 and all subsequent cycles (see Table 1 ). Renal function as measured by CrCl did not affect carfilzomib clearance, exposure, activity, or tolerability across all cohorts. The ORR was 21.3 % with a median TTP of 6.4 months, and the median OS was not reached at the time of data cut-off (see Table 2 ).
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The most common treatment-emergent AEs were fatigue (56.0 %), anemia (50.0 %), and nausea (36.0 %) (see Table 3 ). The overall incidence of grade 1/2 peripheral neuropathy was 10 %. The findings from this study suggest that, similar to other PIs and in contrast to MM treatments such as lenalidomide, carfilzomib dose and schedule do not need to be adjusted in patients with baseline renal dysfunction, including patients on hemodialysis.
Future Directions
Carfilzomib is currently being evaluated in a number of combinations in relapsed and/or refractory disease (e.g., carfilzomib plus lenalidomide or pomalidamide plus dexamethasone [CRd or CPd], CRd plus vorinostat). Encouraging efficacy data have been achieved with these combinations, with data regarding CRd combinations (PX-171-006, ClinicalTrial.gov identifier NCT00603447) being the most mature at the time of writing. 24 Many of these studies are also evaluating higher doses of carfilzomib and using longer infusion times (e.g., 30 minutes) in an effort to enable the delivery of higher doses for potentially greater efficacy and simultaneously improve tolerability. 29 The CRd combination has also been tested in 53 newly diagnosed patients in a Phase I/II study (ClinicalTrial.gov identifier NCT01029054) and achieved a 100 % ORR, 
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